Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner
- 2017-01
- Open Biology 7(1)
- K. R. Hughes
- L. C. Harnisch
- L. C. Harnisch
- Cristina Alcon-Giner
- Suparna Mitra
- C. J. Wright
- C. J. Wright
- Jennifer Ketskemety
- D. Sinderen
- Alastair J.M. Watson
- Lindsay J. Hall
- PubMed: 28123052
- DOI: 10.1098/rsob.160155
Study Design
- Type
- Clinical Trial
- Population
- Mice
- Methods
- In vivo experiment with a mouse model
- Animal Study
Abstract
Certain members of the microbiota genus Bifidobacterium are known to positively influence host well-being. Importantly, reduced bifidobacterial levels are associated with inflammatory bowel disease (IBD) patients, who also have impaired epithelial barrier function, including elevated rates of apoptotic extrusion of small intestinal epithelial cells (IECs) from villi-a process termed 'cell shedding'. Using a mouse model of pathological cell shedding, we show that mice receiving Bifidobacterium breve UCC2003 exhibit significantly reduced rates of small IEC shedding. Bifidobacterial-induced protection appears to be mediated by a specific bifidobacterial surface exopolysaccharide and interactions with host MyD88 resulting in downregulation of intrinsic and extrinsic apoptotic responses to protect epithelial cells under highly inflammatory conditions. Our results reveal an important and previously undescribed role for B. breve, in positively modulating epithelial cell shedding outcomes via bacterial- and host-dependent factors, supporting the notion that manipulation of the microbiota affects intestinal disease outcomes.
Keywords: Bifidobacterium; epithelial cell shedding; exopolysaccharide; inflammatory bowel disease.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|